Strongbridge Biopharma plc
SBBP · NASDAQ
6/30/2021 | 3/31/2021 | 12/31/2020 | 9/30/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 19.8% | 1.9% | 1.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 95.3% | 95.1% | 94.6% | 94.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -111.1% | -116.4% | -123.1% | -16.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -131.9% | -140.9% | -145.2% | -39.1% |
| EPS Diluted | -0.19 | -0.18 | -0.21 | -0.055 |
| % Growth | -5.6% | 14.3% | -281.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |